Immunis, founded in Irvine, California, is a private biotechnology company focused on developing innovative stem cell treatments to combat age and disease-related immune decline. The company's core mission is to enhance the quality of life by reversing immune system deterioration through advanced biotechnological solutions. Immunis offers novel therapeutic products aimed at rejuvenating the immune system, targeting markets primarily concerned with aging populations and chronic disease management.
Notable figures affiliated with Immunis include Chairman Dr. Hans Keirstead, a recognized expert in stem cell research who has been invited to present at the Bio International Convention and received an honorary Ph.D. from the University of New Brunswick. The company has achieved significant milestones, including a partnership with Japanese drug company Toray to address sarcopenia. Immunis's pioneering work in stem cell therapy has positioned it as a key player in the biotech industry, making substantial strides in improving immune health and longevity.
